Harnessing dendritic cells for tumor antigen presentation stefan

Cancers

Volumn 3, Issue 2, 2011, Pages 2195-2213

  Nierkens, N ^a   Janssen, Edith M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antigen presentation; Antigen processing; Dendritic cell; Tumor antigen

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DNA; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CROSS PRESENTATION; DENDRITIC CELL; DNA TRANSFER; DRUG TARGETING; ELECTROPORATION; ENDOCYTOSIS; GENE MUTATION; GENETIC TRANSFECTION; GLIOMA; HLA MATCHING; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; OVARY CANCER; PHAGOCYTOSIS; PINOCYTOSIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 79959726017     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3022195     Document Type: Review

References (135)

1. Inaba, K.; Inaba, M.; Romani, N.; Aya, H.; Deguchi, M.; Ikehara, S.; Muramatsu, S.; Steinman, R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992, 176, 1693-1702.
2. Banchereau, J.; Palucka, A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 2005, 5, 296-306.
3. Nestle, F.O.; Farkas, A.; Conrad, C. Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 2005, 17, 163-169.
4. Schuler, G.; Schuler-Thurner, B.; Steinman, R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 2003, 15, 138-147.
5. Thurner, B.; Roder, C.; Dieckmann, D.; Heuer, M.; Kruse, M.; Glaser, A.; Keikavoussi, P.; Kampgen, E.; Bender, A.; Schuler, G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 1999, 223, 1-15.
6. Bender, A.; Sapp, M.; Schuler, G.; Steinman, R.M.; Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 1996, 196, 121-135.
7. Siena, S.; Di Nicola, M.; Bregni, M.; Mortarini, R.; Anichini, A.; Lombardi, L.; Ravagnani, F.; Parmiani, G.; Gianni, A.M. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp. Hematol. 1995, 23, 1463-1471.
8. Clinical Trials. gov database. http://www.clinicaltrials.gov/ (accessed 20 April 2011).
9. Ueno, H.; Palucka, A.K.; Banchereau, J. The expanding family of dendritic cell subsets. Nat. Biotechnol. 2010, 28, 813-815.
10. Jarnjak-Jankovic, S.; Hammerstad, H.; Saeboe-Larssen, S.; Kvalheim, G.; Gaudernack, G. A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer 2007, 7, 119.
11. Oneill, D.W.; Bhardwaj, N. Differentiation of peripheral blood monocytes into dendritic cells. Curr. Protoc. Immunol. 2005, doi: 10.1002/0471142735.im22f04s67.
12. Mahnke, K.; Schmitt, E.; Bonifaz, L.; Enk, A.H.; Jonuleit, H. Immature, but not inactive: The tolerogenic function of immature dendritic cells. Immunol. Cell. Biol. 2002, 80, 477-483.
13. Cools, N.; Ponsaerts, P.; Van Tendeloo, V.F.; Berneman, Z.N. Balancing between immunity and tolerance: An interplay between dendritic cells, regulatory T cells, and effector T cells. J. Leukoc. Biol. 2007, 82, 1365-1374.
14. Hugues, S.; Boissonnas, A.; Amigorena, S.; Fetler, L. The dynamics of dendritic cell-T cell interactions in priming and tolerance. Curr. Opin. Immunol. 2006, 18, 491-495.
15. Benvenuti, F.; Lagaudriere-Gesbert, C.; Grandjean, I.; Jancic, C.; Hivroz, C.; Trautmann, A.; Lantz, O.; Amigorena, S. Dendritic cell maturation controls adhesion, synapse formation, and the duration of the interactions with naive T lymphocytes. J. Immunol. 2004, 172, 292-301.
16. Guermonprez, P.; Valladeau, J.; Zitvogel, L.; Thery, C.; Amigorena, S. Antigen presentation and T cell stimulation by dendritic cells. Ann. Rev. Immunol. 2002, 20, 621-667.
17. Cella, M.; Scheidegger, D.; Palmer-Lehmann, K.; Lane, P.; Lanzavecchia, A.; Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 1996, 184, 747-752.
18. Schoenberger, S.P.; Toes, R.E.; van der Voort, E.I.; Offringa, R.; Melief, C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393, 480-483.
19. Ridge, J.P.; Di Rosa, F.; Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393, 474-478.
20. Bennett, S.R.; Carbone, F.R.; Karamalis, F.; Flavell, R.A.; Miller, J.F.; Heath, W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393, 478-480.
21. Gallucci, S.; Lolkema, M.; Matzinger, P. Natural adjuvants: Endogenous activators of dendritic cells. Nat. Med. 1999, 5, 1249-1255.
22. Shi, Y.; Evans, J.E.; Rock, K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425, 516-521.
23. Le Bon, A.; Etchart, N.; Rossmann, C.; Ashton, M.; Hou, S.; Gewert, D.; Borrow, P.; Tough, D.F. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 2003, 4, 1009-1015.
24. Lutz, M.B.; Girolomoni, G.; Ricciardi-Castagnoli, P. The role of cytokines in functional regulation and differentiation of dendritic cells. Immunobiology 1996, 195, 431-455.
25. Prlic, M.; Williams, M.A.; Bevan, M.J. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr. Opin. Immunol. 2007, 19, 315-319.
26. Fazilleau, N.; McHeyzer-Williams, L.J.; McHeyzer-Williams, M.G. Local development of effector and memory T helper cells. Curr. Opin. Immunol. 2007, 19, 259-267.
27. Schwartz, J.C.; Zhang, X.; Nathenson, S.G.; Almo, S.C. Structural mechanisms of costimulation. Nat. Immunol. 2002, 3, 427-434.
28. Janssen, E.M.; Lemmens, E.E.; Wolfe, T.; Christen, U.; von Herrath, M.G.; Schoenberger, S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421, 852-856.
29. Shedlock, D.J.; Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300, 337-339.
30. Sun, J.C.; Bevan, M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300, 339-342.
31. Janssen, E.M.; Droin, N.M.; Lemmens, E.E.; Pinkoski, M.J.; Bensinger, S.J.; Ehst, B.D.; Griffith, T.S.; Green, D.R.; Schoenberger, S.P. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005, 434, 88-93.
32. Perez-Diez, A.; Joncker, N.T.; Choi, K.; Chan, W.F.; Anderson, C.C.; Lantz, O.; Matzinger, P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109, 5346-5354.
33. Qin, Z.; Blankenstein, T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000, 12, 677-686.
34. Corthay, A. CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells. Adv. Exp. Med. Biol. 2007, 590, 195-208.
35. Corthay, A.; Skovseth, D.K.; Lundin, K.U.; Rosjo, E.; Omholt, H.; Hofgaard, P.O.; Haraldsen, G.; Bogen, B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005, 22, 371-383.
36. Rakhra, K.; Bachireddy, P.; Zabuawala, T.; Zeiser, R.; Xu, L.; Kopelman, A.; Fan, A.C.; Yang, Q.; Braunstein, L.; Crosby, E.; et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18, 485-498.
37. Bos, R.; Sherman, L.A. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010, 70, 8368-8377.
38. Gadea, B.B.; Joyce, J.A. Tumour-host interactions: Implications for developing anti-cancer therapies. Expert Rev. Mol. Med. 2006, 8, 1-32.
39. Yang, L.; Carbone, D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 2004, 92, 13-27.
40. Ohm, J.E.; Carbone, D.P. Immune dysfunction in cancer patients. Oncology (Williston Park, NY) 2002, 16 (Suppl.1), 11-18.
41. Kavanaugh, D.Y.; Carbone, D.P. Immunologic dysfunction in cancer. Hematol./Oncol. Clin. North Am. 1996, 10, 927-951.
42. Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6, 715-727.
43. Warger, T.; Osterloh, P.; Rechtsteiner, G.; Fassbender, M.; Heib, V.; Schmid, B.; Schmitt, E.; Schild, H.; Radsak, M.P. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006, 108, 544-550.
44. Oneill, D.W.; Adams, S.; Bhardwaj, N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104, 2235-2246.
45. Dhodapkar, M.V.; Steinman, R.M.; Krasovsky, J.; Munz, C.; Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 2001, 193, 233-238.
46. Dhodapkar, M.V.; Steinman, R.M. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002, 100, 174-177.
47. Banerjee, D.K.; Dhodapkar, M.V.; Matayeva, E.; Steinman, R.M.; Dhodapkar, K.M. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006, 108, 2655-2661.
48. De Vries, I.J.; Krooshoop, D.J.; Scharenborg, N.M.; Lesterhuis, W.J.; Diepstra, J.H.; Van Muijen, G.N.; Strijk, S.P.; Ruers, T.J.; Boerman, O.C.; Oyen, W.J.; et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003, 63, 12-17.
49. Jongmans, W.; Tiemessen, D.M.; van Vlodrop, I.J.; Mulders, P.F.; Oosterwijk, E. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: The importance of maturation cocktails. J. Immunother. 2005, 28, 480-487.
50. Kalinski, P.; Schuitemaker, J.H.; Hilkens, C.M.; Wierenga, E.A.; Kapsenberg, M.L. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J. Immunol. 1999, 162, 3231-3236.
51. Luft, T.; Jefford, M.; Luetjens, P.; Toy, T.; Hochrein, H.; Masterman, K.A.; Maliszewski, C.; Shortman, K.; Cebon, J.; Maraskovsky, E. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: Prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 2002, 100, 1362-1372.
52. Parmiani, G.; De Filippo, A.; Novellino, L.; Castelli, C. Unique human tumor antigens: Immunobiology and use in clinical trials. J. Immunol. 2007, 178, 1975-1979.
53. Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.; Weiner, L.M.; et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 2009, 15, 5323-5337.
54. Villadangos, J.A.; Schnorrer, P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. 2007, 7, 543-555.
55. Villadangos, J.A.; Schnorrer, P.; Wilson, N.S. Control of MHC class II antigen presentation in dendritic cells: A balance between creative and destructive forces. Immunol. Rev. 2005, 207, 191-205.
56. Lanzavecchia, A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 1996, 8, 348-354.
57. Lanzavecchia, A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Ann. Rev. Immunol. 1990, 8, 773-793.
58. Tosello, V.; Zamarchi, R.; Merlo, A.; Gorza, M.; Piovan, E.; Mandruzzato, S.; Bronte, V.; Wang, X.; Ferrone, S.; Amadori, A.; et al. Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur. J. Immunol. 2009, 39, 56-66.
59. Cascio, P.; Hilton, C.; Kisselev, A.F.; Rock, K.L.; Goldberg, A.L. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 2001, 20, 2357-2366.
60. Amigorena, S.; Savina, A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol. 2010, 22, 109-117.
61. Kovacsovics-Bankowski, M.; Rock, K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995, 267, 243-246.
62. Rock, K.L. Exiting the outside world for cross-presentation. Immunity 2006, 25, 523-525.
63. Rock, K.L.; Farfan-Arribas, D.J.; Shen, L. Proteases in MHC class I presentation and cross-presentation. J. Immunol. 2010, 184, 9-15.
64. Bougneres, L.; Helft, J.; Tiwari, S.; Vargas, P.; Chang, B.H.; Chan, L.; Campisi, L.; Lauvau, G.; Hugues, S.; Kumar, P.; et al. A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells. Immunity 2009, 31, 232-244.
65. Ploegh, H.L. A lipid-based model for the creation of an escape hatch from the endoplasmic reticulum. Nature 2007, 448, 435-438.
66. Ackerman, A.L.; Giodini, A.; Cresswell, P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 2006, 25, 607-617.
67. Ackerman, A.L.; Kyritsis, C.; Tampe, R.; Cresswell, P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl. Acad. Sci. USA 2003, 100, 12889-12894.
68. Vyas, J.M.; Van der Veen, A.G.; Ploegh, H.L. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 2008, 8, 607-618.
69. Doherty, G.J.; McMahon, H.T. Mechanisms of endocytosis. Annu. Rev. Biochem. 2009, 78, 857-902.
70. Blander, J.M.; Medzhitov, R. On regulation of phagosome maturation and antigen presentation. Nat. Immunol. 2006, 7, 1029-1035.
71. Cancer Immunity Home Page. http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm/ (accessed 20 April 2011).
72. Parmiani, G.; Castelli, C.; Dalerba, P.; Mortarini, R.; Rivoltini, L.; Marincola, F.M.; Anichini, A. Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going? J. Natl. Cancer Inst. 2002, 94, 805-818.
73. Fauquembergue, E.; Toutirais, O.; Tougeron, D.; Drouet, A.; Le Gallo, M.; Desille, M.; Cabillic, F.; de La Pintiere, C.T.; Iero, M.; Rivoltini, L.; et al. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy. J. Immunother. 2010, 33, 402-413.
74. Carrabba, M.G.; Castelli, C.; Maeurer, M.J.; Squarcina, P.; Cova, A.; Pilla, L.; Renkvist, N.; Parmiani, G.; Rivoltini, L. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: Role of Melan-A/MART-1 optimized analogues. Cancer Res. 2003, 63, 1560-1567.
75. Morel, S.; Levy, F.; Burlet-Schiltz, O.; Brasseur, F.; Probst-Kepper, M.; Peitrequin, A.L.; Monsarrat, B.; Van Velthoven, R.; Cerottini, J.C.; Boon, T.; et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000, 12, 107-117.
76. Chapatte, L.; Ayyoub, M.; Morel, S.; Peitrequin, A.L.; Levy, N.; Servis, C.; Van den Eynde, B.J.; Valmori, D.; Levy, F. Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. Cancer Res. 2006, 66, 5461-5468.
77. Chapiro, J.; Claverol, S.; Piette, F.; Ma, W.; Stroobant, V.; Guillaume, B.; Gairin, J.E.; Morel, S.; Burlet-Schiltz, O.; Monsarrat, B.; et al. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 2006, 176, 1053-1061.
78. Gallucci, S.; Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 2001, 13, 114-119.
79. Kono, H.; Chen, C.J.; Ontiveros, F.; Rock, K.L. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J. Clin. Invest. 2010, 120, 1939-1949.
80. Martins, I.; Kepp, O.; Galluzzi, L.; Senovilla, L.; Schlemmer, F.; Adjemian, S.; Menger, L.; Michaud, M.; Zitvogel, L.; Kroemer, G. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann. N. Y. Acad. Sci. 2010, 1209, 77-82.
81. Zitvogel, L.; Kepp, O.; Kroemer, G. Decoding cell death signals in inflammation and immunity. Cell 2010, 140, 798-804.
82. Aymeric, L.; Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Martins, I.; Kroemer, G.; Smyth, M.J.; Zitvogel, L. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010, 70, 855-858.
83. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Criollo, A.; Ortiz, C.; Lidereau, R.; Mariette, C.; Chaput, N.; Mira, J.P.; Delaloge, S.; et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 2007, 220, 47-59.
84. Williams, C.A.; Harry, R.A.; McLeod, J.D. Apoptotic cells induce dendritic cell-mediated suppression via interferon-gamma-induced IDO. Immunology 2008, 124, 89-101.
85. Peng, Y.F.; Elkon, K.B. Peripheral CD8 T-cell responses to apoptotic cell proteins and peptides. Crit. Rev. Immunol. 2007, 27, 357-365.
86. Ferguson, T.A.; Kazama, H. Signals from dying cells: Tolerance induction by the dendritic cell. Immunol. Res. 2005, 32, 99-108.
87. Saas, P.; Bonnefoy, F.; Kury-Paulin, S.; Kleinclauss, F.; Perruche, S. Mediators involved in the immunomodulatory effects of apoptotic cells. Transplantation 2007, 84 (Suppl.1), S31-S34.
88. Tesniere, A.; Panaretakis, T.; Kepp, O.; Apetoh, L.; Ghiringhelli, F.; Zitvogel, L.; Kroemer, G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008, 15, 3-12.
89. Gong, J.; Chen, D.; Kashiwaba, M.; Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 1997, 3, 558-561.
90. Koido, S.; Homma, S.; Hara, E.; Namiki, Y.; Takahara, A.; Komita, H.; Nagasaki, E.; Ito, M.; Ohkusa, T.; Gong, J.; et al. Regulation of tumor immunity by tumor/dendritic cell fusions. Clin. Dev. Immunol. 2010, 516768.
91. Jantscheff, P.; Spagnoli, G.; Zajac, P.; Rochlitz, C.F. Cell fusion: An approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol. Immunother. 2002, 51, 367-375.
92. Phan, V.; Errington, F.; Cheong, S.C.; Kottke, T.; Gough, M.; Altmann, S.; Brandenburger, A.; Emery, S.; Strome, S.; Bateman, A.; et al. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat. Med. 2003, 9, 1215-1219.
93. Marten, A.; Renoth, S.; Heinicke, T.; Albers, P.; Pauli, A.; Mey, U.; Caspari, R.; Flieger, D.; Hanfland, P.; Von Ruecker, A.; et al. Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene. Ther. 2003, 14, 483-494.
94. Avigan, D.E.; George, D.J. Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Clin. Oncol. 2004, 22, 169.
95. Kao, J.Y.; Gong, Y.; Chen, C.M.; Zheng, Q.D.; Chen, J.J. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol. 2003, 170, 3806-3811.
96. DeBenedette, M.A.; Calderhead, D.M.; Ketteringham, H.; Gamble, A.H.; Horvatinovich, J.M.; Tcherepanova, I.Y.; Nicolette, C.A.; Healey, D.G. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J. Immunol. 2008, 181, 5296-5305.
97. Dorrie, J.; Schaft, N.; Muller, I.; Wellner, V.; Schunder, T.; Hanig, J.; Oostingh, G. J.; Schon, M. P.; Robert, C.; Kampgen, E.; Schuler, G. Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. Cancer Immunol. Immunother. 2008, 57, 467-477.
98. Bonehill, A.; Van Nuffel, A.M.; Corthals, J.; Tuyaerts, S.; Heirman, C.; Francois, V.; Colau, D.; van der Bruggen, P.; Neyns, B.; Thielemans, K. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin. Cancer Res. 2009, 15, 3366-3375.
99. Hong, B.; Ren, W.; Song, X.T.; Evel-Kabler, K.; Chen, S.Y.; Huang, X.F. Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells. Cancer Res. 2009, 69, 8076-8084.
100. Wu, T.C.; Guarnieri, F.G.; Staveley-Ocarroll, K.F.; Viscidi, R.P.; Levitsky, H.I.; Hedrick, L.; Cho, K.R.; August, J.T.; Pardoll, D.M. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA 1995, 92, 11671-11675.
101. Su, Z.; Dannull, J.; Yang, B.K.; Dahm, P.; Coleman, D.; Yancey, D.; Sichi, S.; Niedzwiecki, D.; Boczkowski, D.; Gilboa, E.; et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 2005, 174, 3798-3807.
102. Nair, S.K.; Boczkowski, D.; Morse, M.; Cumming, R.I.; Lyerly, H.K.; Gilboa, E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 1998, 16, 364-369.
103. Chen, Y.Z.; Yao, X.L.; Tabata, Y.; Nakagawa, S.; Gao, J.Q. Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy. Clin. Dev. Immunol. 2010, 565643.
104. Smits, E.L.; Anguille, S.; Cools, N.; Berneman, Z.N.; Van Tendeloo, V.F. Dendritic cell-based cancer gene therapy. Hum. Gene Ther. 2009, 20, 1106-1118.
105. Okada, N.; Mori, N.; Koretomo, R.; Okada, Y.; Nakayama, T.; Yoshie, O.; Mizuguchi, H.; Hayakawa, T.; Nakagawa, S.; Mayumi, T.; et al. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 2005, 12, 129-139.
106. Youlin, K.; Xiaodong, W.; Xiuheng, L.; Zhiyuan, C.; Hengcheng, Z.; Hui, C.; Botao, J. The change of immunoactivity of dendritic cells induced by mouse 4-1BBL recombinant adenovirus. Yonsei Med. J. 2010, 51, 594-598.
107. Gonzalez-Carmona, M.A.; Lukacs-Kornek, V.; Timmerman, A.; Shabani, S.; Kornek, M.; Vogt, A.; Yildiz, Y.; Sievers, E.; Schmidt-Wolf, I.G.; Caselmann, W.H.; et al. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 2008, 48, 157-168.
108. Bonini, C.; Lee, S.P.; Riddell, S.R.; Greenberg, P.D. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J. Immunol. 2001, 166, 5250-5257.
109. Muruve, D.A.; Cotter, M.J.; Zaiss, A.K.; White, L.R.; Liu, Q.; Chan, T.; Clark, S.A.; Ross, P.J.; Meulenbroek, R.A.; Maelandsmo, G.M.; et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J. Virol. 2004, 78, 5966-5972.
110. Roth, M.D.; Cheng, Q.; Harui, A.; Basak, S.K.; Mitani, K.; Low, T.A.; Kiertscher, S.M. Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J. Immunol. 2002, 169, 4651-4656.
111. Lapointe, R.; Royal, R.E.; Reeves, M.E.; Altomare, I.; Robbins, P.F.; Hwu, P. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J. Immunol. 2001, 167, 4758-4764.
112. Szabolcs, P.; Gallardo, H.F.; Ciocon, D.H.; Sadelain, M.; Young, J.W. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood 1997, 90, 2160-2167.
113. Bello-Fernandez, C.; Matyash, M.; Strobl, H.; Pickl, W.F.; Majdic, O.; Lyman, S.D.; Knapp, W. Efficient retrovirus-mediated gene transfer of dendritic cells generated from CD34+ cord blood cells under serum-free conditions. Hum. Gene. Ther. 1997, 8, 1651-1658.
114. Esslinger, C.; Romero, P.; MacDonald, H.R. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum. Gene Ther. 2002, 13, 1091-1100.
115. Lizee, G.; Gonzales, M.I.; Topalian, S.L. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gene Ther. 2004, 15, 393-404.
116. Li, G.B.; Lu, G.X. Gene delivery efficiency in bone marrow-derived dendritic cells: Comparison of four methods and optimization for lentivirus transduction. Mol. Biotechnol. 2009, 43, 250-256.
117. Yang, L.; Yang, H.; Rideout, K.; Cho, T.; Joo, K.I.; Ziegler, L.; Elliot, A.; Walls, A.; Yu, D.; Baltimore, D.; et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 2008, 26, 326-334.
118. Montini, E.; Cesana, D.; Schmidt, M.; Sanvito, F.; Ponzoni, M.; Bartholomae, C.; Sergi Sergi, L.; Benedicenti, F.; Ambrosi, A.; Di Serio, C.; et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 2006, 24, 687-696.
119. Bosticardo, M.; Ghosh, A.; Du, Y.; Jenkins, N.A.; Copeland, N.G.; Candotti, F. Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells. Mol. Ther. 2009, 17, 1910-1918.
120. Nienhuis, A.W.; Dunbar, C.E.; Sorrentino, B.P. Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 2006, 13, 1031-1049.
121. Seggewiss, R.; Pittaluga, S.; Adler, R.L.; Guenaga, F.J.; Ferguson, C.; Pilz, I.H.; Ryu, B.; Sorrentino, B.P.; Young, W.S.,; Donahue, R.E.; et al. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 2006, 107, 3865-3867.
122. Lapenta, C.; Santini, S.M.; Spada, M.; Donati, S.; Urbani, F.; Accapezzato, D.; Franceschini, D.; Andreotti, M.; Barnaba, V.; Belardelli, F. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur. J. Immunol. 2006, 36, 2046-2060.
123. Santini, S.M.; Lapenta, C.; Belardelli, F. Type I interferons as regulators of the differentiation/activation of human dendritic cells: Methods for the evaluation of IFN-induced effects. Methods Mol. Med. 2005, 116, 167-181.
124. Nair, S.; McLaughlin, C.; Weizer, A.; Su, Z.; Boczkowski, D.; Dannull, J.; Vieweg, J.; Gilboa, E. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 2003, 171, 6275-6282.
125. Wu, T.L.; Ertl, H.C. Immune barriers to successful gene therapy. Trends Mol. Med. 2009, 15, 32-39.
126. Ko, K.; Yamazaki, S.; Nakamura, K.; Nishioka, T.; Hirota, K.; Yamaguchi, T.; Shimizu, J.; Nomura, T.; Chiba, T.; Sakaguchi, S. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 2005, 202, 885-891.
127. Liu, J.Y.; Wu, Y.; Zhang, X.S.; Yang, J.L.; Li, H.L.; Mao, Y.Q.; Wang, Y.; Cheng, X.; Li, Y.Q.; Xia, J.C.; et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol. Immunother. 2007, 56, 1597-1604.
128. Cohen, A.D.; Diab, A.; Perales, M.A.; Wolchok, J.D.; Rizzuto, G.; Merghoub, T.; Huggins, D.; Liu, C.; Turk, M.J.; Restifo, N.P.; et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 2006, 66, 4904-4912.
129. Duvic, M.; Talpur, R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008, 4, 457-469.
130. Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 2002, 99, 12293-12297.
131. Fujita, T.; Teramoto, K.; Ozaki, Y.; Hanaoka, J.; Tezuka, N.; Itoh, Y.; Asai, T.; Fujino, S.; Kontani, K.; Ogasawara, K. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res. 2009, 69, 5142-5150.
132. Kocak, E.; Lute, K.; Chang, X.; May, K.F., Jr.; Exten, K.R.; Zhang, H.; Abdessalam, S.F.; Lehman, A.M.; Jarjoura, D.; Zheng, P.; et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 2006, 66, 7276-7284.
133. Teague, R.M.; Sather, B.D.; Sacks, J.A.; Huang, M.Z.; Dossett, M.L.; Morimoto, J.; Tan, X.; Sutton, S.E.; Cooke, M.P.; Ohlen, C.; et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 2006, 12, 335-341.
134. Schluns, K.S.; Kieper, W.C.; Jameson, S.C.; Lefrancois, L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 2000, 1, 426-432.
135. May, K.F., Jr.; Chen, L.; Zheng, P.; Liu, Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 2002, 62, 3459-3465.